全文获取类型
收费全文 | 21242篇 |
免费 | 1314篇 |
国内免费 | 168篇 |
专业分类
耳鼻咽喉 | 283篇 |
儿科学 | 567篇 |
妇产科学 | 760篇 |
基础医学 | 2433篇 |
口腔科学 | 624篇 |
临床医学 | 1594篇 |
内科学 | 4014篇 |
皮肤病学 | 447篇 |
神经病学 | 1059篇 |
特种医学 | 784篇 |
外国民族医学 | 12篇 |
外科学 | 3838篇 |
综合类 | 455篇 |
现状与发展 | 2篇 |
一般理论 | 14篇 |
预防医学 | 1712篇 |
眼科学 | 682篇 |
药学 | 2041篇 |
中国医学 | 149篇 |
肿瘤学 | 1254篇 |
出版年
2023年 | 248篇 |
2022年 | 235篇 |
2021年 | 1150篇 |
2020年 | 681篇 |
2019年 | 849篇 |
2018年 | 1170篇 |
2017年 | 668篇 |
2016年 | 723篇 |
2015年 | 738篇 |
2014年 | 1000篇 |
2013年 | 1190篇 |
2012年 | 1714篇 |
2011年 | 1864篇 |
2010年 | 1049篇 |
2009年 | 799篇 |
2008年 | 1115篇 |
2007年 | 1121篇 |
2006年 | 1039篇 |
2005年 | 977篇 |
2004年 | 871篇 |
2003年 | 798篇 |
2002年 | 719篇 |
2001年 | 196篇 |
2000年 | 168篇 |
1999年 | 147篇 |
1998年 | 101篇 |
1997年 | 92篇 |
1996年 | 71篇 |
1995年 | 86篇 |
1994年 | 68篇 |
1993年 | 54篇 |
1992年 | 87篇 |
1991年 | 87篇 |
1990年 | 80篇 |
1989年 | 74篇 |
1988年 | 73篇 |
1987年 | 59篇 |
1986年 | 49篇 |
1985年 | 51篇 |
1984年 | 49篇 |
1983年 | 43篇 |
1982年 | 45篇 |
1981年 | 31篇 |
1980年 | 28篇 |
1979年 | 19篇 |
1978年 | 25篇 |
1977年 | 22篇 |
1976年 | 23篇 |
1974年 | 25篇 |
1973年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Saleh A Alqahtani Massimo G Colombo 《World journal of gastrointestinal oncology》2021,13(12):2038-2049
Globally, hepatocellular carcinoma (HCC) is a frequently diagnosed malignancy with rapidly increasing incidence and mortality rates. Unfortunately, many of these patients are diagnosed in the advanced stages when locoregional treatments are not appropriate. Before 2008, no effective drug treatments existed to prolong survival, until the breakthrough multi-tyrosine kinase inhibitor (TKI) sorafenib was developed. It remained the standard treatment option for advanced HCC for 10 years, with a battery of other candidate drugs in clinical trials failing to produce similar efficacy results. In 2018, the REFLECT trial introduced another multi-TKI, lenvatinib, which has non-inferior overall survival compared with sorafenib. Thus, offering patients and their treating physicians two effective treatment options. Recently, immunotherapy-based drugs, such as atezolizumab and bevacizumab, have shown promising results in patients with unresectable HCC. This review summarizes clinical trial and real-world data studies of sorafenib and lenvatinib in patients with unresectable HCC. We offer guidance on the optimal choice between the two treatments and discuss the potential of immunotherapy-based combination; when more data become available, this will likely make the choice between sorafenib and lenvatinib somewhat obsolete. 相似文献
6.
Sania Amr Magdy Garas Dina N. K. Boulos Doa’a A. Saleh Irene A. Jillson Christopher A. Loffredo 《Journal of substance use》2019,24(3):341-345
Background: Egyptian street youth use substances including tobacco, illicit drugs, and pharmaceutical drugs. To understand the circumstances, including adverse childhood experiences, that place adolescents at risk for engaging in substance use, we conducted in-depth interviews among a sample of Egyptian street children. Methods: From youth residing at or attending Caritas, a non-profit organization, which provides shelter and education to street youth, seven girls and twelve boys, aged 12–18 years, participated in open-ended, in-depth interviews. Results: Eight out of the 19 participants reported family history (early exposure) to substance use; and seven of them were initiated by either a family member (sibling), friend or coworker. Most of the participants reported a history of conflict with or abuse (verbal or physical) by their parents or siblings, or stressful situations at home; they used substance(s) to alleviate their stress. Few attended school, and some were forced to work and help their family. Conclusions: Among Egyptian youth, adverse childhood experiences, such as poverty, child abuse, and family substance use, challenge somewhat susceptible youths and lead them to the path of substance use and addiction. Prevention intervention should be multifaceted, culturally adaptable, and primarily targeting the social environment during childhood. 相似文献
7.
8.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献9.
Walid K. Abu Saleh Phillip Mason Odeaa Al Jabbari Hany Samir Brian A. Bruckner 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(6):569-571
The Impella 5.0, a percutaneously inserted left ventricular assist device, has been used to support patients who have severe heart failure or who are undergoing high-risk percutaneous coronary intervention. We report our surgical placement of the Impella 5.0, through a graft sewn to the aorta, to unload the left ventricle of a 59-year-old man who was undergoing venoarterial extracorporeal membrane oxygenation for postcardiotomy shock. The patient underwent successful placement of a long-term left ventricular assist device before his discharge from the hospital. The versatility of the Impella 5.0 is exemplified in this patient who was successfully bridged to long-term support. 相似文献
10.
Femoral access‐related complications during percutaneous transcatheter aortic valve implantation comparing single versus double Prostar XL device closure 下载免费PDF全文